Campbell & CO Investment Adviser LLC Makes New $1.06 Million Investment in Medpace Holdings, Inc. $MEDP

Campbell & CO Investment Adviser LLC purchased a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,374 shares of the company’s stock, valued at approximately $1,059,000.

Several other hedge funds also recently modified their holdings of MEDP. Invesco Ltd. grew its position in Medpace by 9.4% during the 1st quarter. Invesco Ltd. now owns 1,186,768 shares of the company’s stock worth $361,596,000 after acquiring an additional 102,015 shares during the last quarter. Mawer Investment Management Ltd. acquired a new stake in shares of Medpace during the first quarter valued at about $212,131,000. AQR Capital Management LLC grew its holdings in shares of Medpace by 12.4% during the first quarter. AQR Capital Management LLC now owns 539,547 shares of the company’s stock worth $158,470,000 after purchasing an additional 59,361 shares during the last quarter. TD Asset Management Inc increased its stake in shares of Medpace by 15.6% in the second quarter. TD Asset Management Inc now owns 457,645 shares of the company’s stock valued at $143,636,000 after buying an additional 61,764 shares during the period. Finally, Northern Trust Corp raised its holdings in Medpace by 36.0% in the 1st quarter. Northern Trust Corp now owns 337,489 shares of the company’s stock valued at $102,830,000 after buying an additional 89,347 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Stock Performance

Shares of MEDP stock opened at $597.60 on Thursday. The company has a market capitalization of $16.83 billion, a price-to-earnings ratio of 41.79, a PEG ratio of 2.67 and a beta of 1.42. The company has a 50-day simple moving average of $535.14 and a two-hundred day simple moving average of $419.62. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $625.00.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.36. The business had revenue of $659.90 million for the quarter, compared to analysts’ expectations of $640.49 million. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The business’s revenue was up 23.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.01 earnings per share. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, sell-side analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

MEDP has been the topic of a number of research reports. William Blair reissued a “market perform” rating on shares of Medpace in a report on Wednesday, July 23rd. TD Cowen boosted their price objective on shares of Medpace from $356.00 to $462.00 and gave the stock a “sell” rating in a research note on Friday, October 24th. UBS Group downgraded shares of Medpace from a “neutral” rating to a “sell” rating and increased their target price for the company from $300.00 to $305.00 in a research report on Tuesday, July 29th. Cowen reiterated a “sell” rating on shares of Medpace in a report on Friday, October 24th. Finally, Wall Street Zen raised shares of Medpace from a “hold” rating to a “buy” rating in a research report on Saturday, October 25th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, nine have issued a Hold rating and four have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $475.90.

Insider Activity

In related news, CEO August J. Troendle sold 36,196 shares of Medpace stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $475.90, for a total value of $17,225,676.40. Following the sale, the chief executive officer owned 925,799 shares of the company’s stock, valued at approximately $440,587,744.10. The trade was a 3.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Susan E. Burwig sold 18,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $605.00, for a total value of $10,890,000.00. Following the completion of the transaction, the vice president owned 47,500 shares in the company, valued at approximately $28,737,500. The trade was a 27.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 134,211 shares of company stock worth $74,459,958. 20.30% of the stock is owned by insiders.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.